<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://www.feuxdelamour.com/v4/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="fr">
		<id>http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=The_Dialogue_Over_Callous_Pazopanib-Concepts</id>
		<title>The Dialogue Over Callous Pazopanib-Concepts - Historique des versions</title>
		<link rel="self" type="application/atom+xml" href="http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=The_Dialogue_Over_Callous_Pazopanib-Concepts"/>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=The_Dialogue_Over_Callous_Pazopanib-Concepts&amp;action=history"/>
		<updated>2026-06-16T18:53:57Z</updated>
		<subtitle>Historique pour cette page sur le wiki</subtitle>
		<generator>MediaWiki 1.20alpha</generator>

	<entry>
		<id>http://www.feuxdelamour.com/v4/index.php?title=The_Dialogue_Over_Callous_Pazopanib-Concepts&amp;diff=95577&amp;oldid=prev</id>
		<title>Sextown39 : Page créée avec « 9 to 2.8 per 1000 (P [http://www.selleckchem.com/products/i-bet-762.html I-BET-762 molecular weight] detection because of improvement in echocardiography. Decrease in diag... »</title>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=The_Dialogue_Over_Callous_Pazopanib-Concepts&amp;diff=95577&amp;oldid=prev"/>
				<updated>2017-04-29T20:20:50Z</updated>
		
		<summary type="html">&lt;p&gt;Page créée avec « 9 to 2.8 per 1000 (P [http://www.selleckchem.com/products/i-bet-762.html I-BET-762 molecular weight] detection because of improvement in echocardiography. Decrease in diag... »&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Nouvelle page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;9 to 2.8 per 1000 (P [http://www.selleckchem.com/products/i-bet-762.html I-BET-762 molecular weight] detection because of improvement in echocardiography. Decrease in diagnosis of severe CHD could be due to the impact of pregnancy termination. &amp;quot;&amp;quot;An unavoidable outcome of cystic fibrosis newborn screening (CF NBS) programs is the detection of infants with an indeterminate diagnosis. The United States CF Foundation recently proposed the term cystic fibrosis transmembrane conductance regulator related [http://en.wikipedia.org/wiki/Fluvoxamine Fluvoxamine] metabolic syndrome (CRMS) to describe infants with elevated immunoreactive trypsinogen (IRT) on NBS who do not meet diagnostic criteria for CF. The objective of this study was to describe the clinical outcomes of infants with CRMS identified through an IRT/DNA algorithm. We reviewed the records of all infants with CRMS diagnosed at our CF Center from 2002 to 2010. We identified 12 infants, and compared them to 27 infants diagnosed with CF by NBS. Compared to CF patients, CRMS patients were more likely to be pancreatic sufficient as assessed by fecal elastase measurement (100% vs. 8%, P?[http://www.selleckchem.com/products/Pazopanib-Hydrochloride.html Pazopanib order] and be hospitalized for pulmonary symptoms. Our results indicate that CRMS patients can develop signs of CF disease, but have a milder clinical course than CF infants. Close initial monitoring of these patients is warranted. Pediatr. Pulmonol. 2011; 46:1079�C1084. ? 2011 Wiley Periodicals, Inc. &amp;quot;&amp;quot;Department of Pediatric Respiratory Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia This case report describes an unusual outcome of ABCA3 deficiency with resolution of symptoms, normalization of chest imaging and lung function in a 9-year-old child whose sibling died of the same disease in infancy. Pediatr Pulmonol. 2013; 48:1035�C1038. ? 2013 Wiley Periodicals, Inc.&lt;/div&gt;</summary>
		<author><name>Sextown39</name></author>	</entry>

	</feed>